Zhou SL, Wang LD. Circulating microRNAs: Novel biomarkers for esophageal cancer. World J Gastroenterol 2010; 16(19): 2348-2354
Corresponding Author of This Article
Li-Dong Wang, Professor, MD, PhD, Cancer Research Center, Xinxiang Medical University, East of Jinsui Road, Xinxiang 453003, Henan Province, China. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Circulating microRNAs: Novel biomarkers for esophageal cancer
Sheng-Li Zhou, Li-Dong Wang
Sheng-Li Zhou, Li-Dong Wang, Cancer Research Center, Xinxiang Medical University, Xinxiang 453003, Henan Province, China; Henan Key Laboratory for Esophageal Cancer Research, Basic Medical College, Zhengzhou University, Zhengzhou 450052, Henan Province, China
ORCID number: $[AuthorORCIDs]
Author contributions: Zhou SL and Wang LD contributed equally to this work.
Correspondence to: Li-Dong Wang, Professor, MD, PhD, Cancer Research Center, Xinxiang Medical University, East of Jinsui Road, Xinxiang 453003, Henan Province, China. firstname.lastname@example.org
Telephone: +86-371-66658335 Fax: +86-371-66658335
Received: February 7, 2010 Revised: March 19, 2010 Accepted: March 26, 2010 Published online: May 21, 2010
Esophageal carcinogenesis is a multi-stage process, involving a variety of changes in gene expression and physiological structure change. MicroRNAs (miRNAs) are a class of small non-coding endogenous RNA molecules. Recent innovation in miRNAs profiling technology have shed new light on the pathology of esophageal carcinoma (EC), and also heralded great potential for exploring novel biomarkers for both EC diagnosis and treatment. Frequent dysregulation of miRNA in malignancy highlights the study of molecular factors upstream of gene expression following the extensive investigation on elucidating the important role of miRNA in carcinogenesis. We herein present a thorough review of the role of miRNAs in EC, addressing miRNA functions, their putative role as oncogenes or tumor suppressors and their potential target genes. The recent progresses in discovering the quantifiable circulating cancer-associated miRNAs indicate the potential clinical use of miRNAs as novel minimally invasive biomarkers for EC and other cancers. We also discuss the potential role of miRNAs in detection, screening and surveillance of EC as miRNAs can be a potential target in personalized treatment of EC.
Esophageal cancer (EC) is the eighth most common cancer and the sixth most common cause of cancer death worldwide, affecting more male than female. The dramatic geographic difference in incidence is the striking characteristic for EC. The EC incidence in the high-risk northern Chinese exceeds 100/10 0000, while that in the low-risk western Africa can be 20-fold lower. EC remains the leading cause of cancer-related death in the high-risk areas, especially in Henan Province, northern China. Esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are the two main forms of EC; each of them has different etiologic and pathologic characteristics. ESCC remains the predominant subtype of EC, especially in China; in contrast, EAC is the most common type in Western countries.
The survival and prognosis of EC patients depend on the stage of the tumor at the time of detection. Despite significant investment and advances in the treatment of cancer, the overall survival for advanced and metastatic cancer is still dismal, with a 5-year survival rate of less than 15% for advanced tumors[1,4,5]. The concept of early detection of esophageal cancer has been established among clinicians and scientists for years. The 5-year survival rate was more than 90% for early EC[1,4,5], about 50% of cancers extend beyond the primary local region at the time of diagnosis and almost 75% of surgically treated patients have proximal lymph node metastasis. At present, gastrointestinal endoscopy remains the primary screening tool, by which the suspected lesions can be biopsied for histopathological analysis. This invasive test, even though it is proved to increase the detection of early tumor and therefore can prolong the survival of the patient, is generally considered to be inconvenient and painful. Because of its limitation, there is an urgent request for discovery of novel predictive markers for EC.
Micro ribonucleic acids (miRNAs) are a class of single-stranded, evolutionarily conserved non-coding RNAs, only 17-25 ribonucleotides long. The first known microRNA (miRNA), the lin-4, was discovered in 1993 through the study of heterochronic gene lin-14 in worms. Since then, miRNA has shown the great potential regulating roles in many aspects of biological and pathological processes. The miRBase, which is the international registries for miRNAs, clearly described their nomenclature, targets and functions and implications in different diseases. The biogenesis of miRNAs is a multi-step process involving a complex protein system, which includes members of the Argonaute family, Pol II-dependent transcription and the RNase IIIs Drosha and Dicer. MiRNAs are involved in crucial biological processes, including development, differentiation, apoptosis and proliferation[11,12]. The mechanism is still under debate, but probably related to inhibition of translation and messenger RNA degradation. These small RNAs regulate gene expression at the level of translation through imperfect pairing with target messenger RNAs (mRNAs) of protein-coding genes. The specific region in miRNA, which is important for messenger RNA target recognition, is referred to as the “seed sequence”, and located at the 5- end of the mature miRNA sequence, from bases 2 to 8. With the seed sequence, we can search for the complementary sequences in the 3’-un-translated regions (3’-UTRs) of known genes that exhibit conservation across species. In animals, most miRNAs are thought to form imperfect base pairs with their target mRNA(s) and these interaction sites are enriched in 3’-UTRs. To date, in the human genome, over 700 mature miRNAs have been identified, and the number is still increasing with the future studies. Up to 1000 miRNAs have been predicated by the bioinformatics studies of the human genome.
EXPERIMENTAL TECHNIQUES FOR MIRNA ANALYSIS
It is necessary to explore effective tools for detection, quantification, and functional analysis of miRNAs. Oligonucleotide miRNA microarray analysis has been extensively used as high-throughput technique for the assessment of cancer-specific expression levels in a large number of samples[10,13,15]. Another method to gauge miRNA expression level includes utilizing a bead-based flow-cytometric technique by which hybridization occurs in solution and provides a high specificity for closely related miRNAs. The miRNA microarray platform with locked nucleic acid-modified capture probes can improve probe thermo-stability and increase specificity, so that it can discriminate miRNAs with even single nucleotide differences. Quantitative real-time polymerase chain reaction (PCR) have also been widely applied to miRNA research because of its cost-effectiveness, high throughput and superior detection of low-abundance species. All of these technologies facilitating miRNAs expression profiling are essential for validation of microarray data.
It is also necessary to develop methods of manipulating miRNA expression for elucidating biological significance and manipulating miRNA expression. MiRNA inhibitors such as 2-O-Methyl antisense single-strand oligonucleotides and locked nucleic acid modified oligonucleotides, made the suppression of endogenous miRNA activity and its downstream effect on messenger RNA expression possible. The latest improvement of miRNA inhibition could control miRNA expression in vivo by expressing decoy miRNA targets via lentiviral vectors, with it we can inhibit specific miRNA by expressing various miRNA inhibitors. MiRNA mimicry could be used to identify the cellular processes and phenotypic changes through transfecting specific miRNAs into cell lines. Although these techniques are of different strength and weakness, the large size studies have shown common characteristics of miRNA deregulation in human cancers and shed light on the application of miRNAs as novel biomarkers finally.
MIRNA AND EC
Early studies demonstrated the aberrant expression of miRNA in cancers and the fact that approximately half of miRNA genes are localized in cancer-associated genomic regions or in fragile sites indicates the potential role of miRNAs as a promising class of oncogenes or tumor suppressor gene in human carcinogenesis. MiRNAs still largely intact in conventionally collected, formalin-fixed and paraffin-embedded tissues and even a modest number of miRNAs are adequate to discriminate human tumors according to the developmental lineage and differentiation state of the tumors. Furthermore, compared with messenger RNA (mRNA) profiles, it is easier to use these miRNA expression profiles to classify poorly differentiated tumors. Here, we will focus on the miRNA expression profiles of EC, especially ESCC, to reveal the oncogenic mechanism by miRNA mediated post-transcriptional pathway. We will first discuss the identification of EC specific miRNA signatures for a new class of screening, diagnostic and prognostic biomarkers through miRNA expression profiling of EC; then we will concentrate on how to clarify the functional roles of miRNA in EC and the potential clinical valuation of the circulating miRNAs in EC. We believe that the study of miRNA’s role in EC will provide new sight into this disease.
Role of miRNAs in carcinogenesis, progression, invasion and metastasis of EC
MiRNA acts as oncomiRNA or tumor suppressors to affect the tumorigenesis if their target mRNAs were encoded by tumor suppressor genes or ontogenesis. Aberrant miRNA expression has been identified and confirmed in EC (Table 1). Comparing the miRNAs expression in ESCC with EAC, we can find that only a few miRNAs expressions were the same in these two diseases, each of which has the different miRNAs expression profiling, indicating that both of ESCC and EAC have distinct etiologic and pathologic characteristics. The miRNAs which are highly expressed in tumor can act as tumor promoter by targeting and inhibiting different tumor suppressor genes such as B-cell CLL/lymphoma 2 (BCL2), tension homologue gene (PTEN), large tumor suppressor homolog 2 (LAST2), annexin A1 (ANXA1). Those genes were all studied in EC tissues and it was suggested that all of them were involved in carcinogenesis of esophagus. Those mature miRNAs with relatively lower expression in cancer may act as tumor suppressor miRNAs. The loss of such miRNAs may enhance the activity of oncogenes.
Table 1 Differential expression of miRNAs in EC tissues compared with normal tissue as identified in seven studies.
Apart from identifying different cancer-related miRNAs, efforts have been made to identify their target genes, messenger RNAs and receptors, which will lead to further studies about their contribution in cancer treatment. For example, the putatively identified targets[31,32,34] of miR-21 are BCL2, PTEN, tumor suppressor gene tropomyosin 1 (TPM1), programmed cell death 4 (PDCD4) and maspin. Zhu et al found that the biological function of miR-21 is probably due to the simultaneous repression of multiple tumor suppressor genes, including PTEN, TPM1, PDCD4, and maspin. PTEN is capable of restricting growth and survival signals by limiting the activity of the phosphoinositide 3-kinase (PI3K)/AKT pathway. A decrease in functional PTEN causes constitutive activation of downstream components of the PI3K/AKT pathway, leading to tumor progression and metastasis. Thus, down-regulation of PTEN by miR-21 may contribute to transformation and increased tumor cell survival. TPM1 is an actin-binding protein which is capable of stabilizing microfilaments, regulating both microfilament organization and anchorage-independent growth, so its importance in cell transformation has been highlighted. Another important mechanism of cancer development is epigenetic silencing of tumor suppressor genes. DNA hypomethylation, CpG island hypermethylation and histone-modification losses represent epigenetic markers of malignant transformation. Calin et al showed that some miRNA (e.g. miR-127) are located in a CpG island, a region that is involved in several types of translocations identified in hematological cancers and deleted by loss of heterozygosity in solid tumors. This phenomenon gives us a clue that the expression of tumor suppressor can be altered in epigenetic silencing mechanism through expression of miRNA.
Dysplasia and Barrett’s esophagus are precursors of EC and the progression of these lesions to cancer is a multistep process that involves different sequential DNA aberrations and changes in gene expression. MiRNA expression profiles in tissues of Barrett’s esophagus with high-grade dysplasia were significantly different from their corresponding normal tissues/EAC tissues, but, no significant difference was found between low-grade dysplasia and paired normal tissues. These observations were consistent with the finding of Feber et al, which suggests that low-grade dysplasia was with a lower malignant transformation rate compared with high-grade dysplasia. Yang et al found that seven miRNAs (hsa-let-7b, hsa-let-7a, hsalet-7c, hsa-let-7f, hsa-miR-345, hsa-miR-494, and hsa-miR-193a) were potentially important in the progression from high-grade dysplasia to EAC. Hsa-let-7b, hsa-let-7a, hsalet-7c and hsa-let-7f belong to the let-7 miRNA family, most of their members function as tumor suppressors through negative regulation of the RAS gene. Accordingly, RAS mutations and amplifications have been frequently identified in precancerous tissues and EC tissues[39,40]. Oncogene RAS may play a role in cell growth and differentiation.
Diagnostic and prognostic value of miRNA for EC
To date, the available data of miRNA expression profile in cancer suggest that miRNA may have diagnostic and prognostic potential. It is crucial to correlate miRNA expression with tumor subtypes or clinical parameters.
Lu et al were the first to systematically demonstrate that the specific miRNA expression can be applied not only for diagnosis but also for classification of different tumors, and the accuracy is 70%. Guo et al were the first to investigate the expression of miRNA in EC tissues using miRNA microarray techniques. They found that five miRNAs (miR-335, miR-181d, miR-25, miR-7 and hsa-miR-495) correlate with gross pathologic classification (fungating vs medullary) and two miRNAs (miR-25 and miR-130b) correlate with differentiation classification (high vs middle vs low). The miRNA expression profiling of ESCC is distinct from EAC. Compared with its expression in normal epithelium (NSE), miR-194, miR-192 and miR200c are significantly up-regulated in EAC but not in ESCC. Oppositely, miR-342 is aberrantly expressed in ESCC but not in EAC. Furthermore, the miRNA expression profiling of NSE and SCC samples are more similar to each other than to the EAC samples. The Barrett’s esophagus (BE) samples sit between the EAC and NSE and one high-grade dysplasia specimen has a miRNA expression profile similar to the EAC. This makes good biological sense that miRNA expression profiles can distinguish esophageal tumorigenesis and may be proven useful for identifying BE patients who are at high risk for progression to EAC.
As we mentioned before, the survival and prognosis of EC is dismal. Therefore, the discovery of new prognostic markers could be a prodigious advantage for identification of patients that would benefit from more aggressive therapy. The high expression of both miR-103 and miR-107 has been shown to correlate with poor survival in 53 Chinese patients with ESCC either by univariate analysis or by multivariate analyses. In an independent study of 30 Japanese patients with ESCC, overexpression of miR-129 was found to significantly correlate with a shorter survival and miR-129 was identified as a significant and independent prognostic factor in surgically treated ESCC patients. The largest study so far, found that low expression of miR-375 in EAC patients was strongly associated with worse prognosis, whereas ESCC patients with high expression of miR-21 had poor prognosis. An earlier study conducted by Sugito et al, measured the expression levels of DICER1, DGCR8, and RNASEN messenger RNA in 73 surgically treated ESCC patients by real-time reverse-transcription PCR, and clarified that high RNASEN expression correlate with poor prognosis in ESCC, indicating that RNASEN may be a good candidate for molecular prognostic marker. Altered expression of these miRNAs is tissue specific, which may provide clues as to the different molecular progression undertaken by these cancers, and opens a potential avenue for targeted therapy to improve prognosis.
Circulating microRNAs: Novel minimally invasive biomarkers for EC
Scientists studying on EC are continually dedicated to search for sensitive, and minimally invasive markers which can detect early neoplastic changes, thus identifying EC at an early stage, as well as monitoring the progress of patients with EC and their response to treatment. Existing methods for identification of EC have many inherent deficiencies. Endoscopic biopsy and histopathological examinations are currently the golden standard diagnostic methods for EC. However, it has limitations, including the use of invasive tool and limited number of experienced physicians. Besides, it is difficult to be applied in large-scale studies because of its tedious approaches. To date, there are still no other effective biomarkers established in the routine assessment of EC.
The much desirable biomarker should be sensitive enough and easily accessible to detect the cancer patients at early stage. Recent studies have shown that tumor-derived miRNAs are resistant to endogenous ribonuclease activity so it can be present in human serum in remarkably stable form. Furthermore, the expression level of serum miRNAs is reproducible and consistent among individuals[43,44]. These tumor-derived miRNAs are present in the circulating blood at levels sufficient to be measurable as biomarkers for the detection of tumors and more than 100 circulating miRNAs can be detected in the blood of healthy individuals. Either plasma or serum can be used for identification of these blood-based biomarkers because the miRNAs levels in plasma and serum are strongly correlated[43,45]. Chen et al demonstrated that the colorectal cancer patients shared a large number of serum miRNAs with lung cancer patients. Moreover, they identified a unique expression profile of serum miRNAs for colorectal cancers that were not present in lung cancer. Though miRNA research is only emerging recently, it has aroused great interest in clinical and scientific communities. Since the presence of miRNA in serum was first described in patients with diffusive large B-cell lymphoma, a number of studies on other solid cancers (ovarian cancer[47,48], lung cancer[49,50], breast cancer, colorectal cancer[52,53]) have been reported about the presence of miRNA in circulation and their potential for use as novel biomarkers. Taylor et al demonstrated that the expression of 8 miRNAs in the serum of patients with ovarian cancer were significantly distinct from their expression observed in benign diseases, yet could not be detected in the serum of healthy controls. Another study indicated that miRNA levels were significantly different between lung cancer patients and controls. Both of these studies suggested that there was no significant difference in the miRNA expression between peripheral circulation and tumors tissues[48,49], indicating that circulating miRNA could act as surrogate of tissue miRNA for early diagnosis. And this will initiate a new application that will be widespread in clinical treatment and disease prevention.
Blood-based miRNAs provide a novel class of minimal invasive biomarkers for high-risk subject screening and early diagnosis for cancers. At the time of writing, there was no article about circulating miRNAs profile of EC. We focus on the circulating miRNA expression profiles of ESCC which is the main type of EC, especially in Asia. Checking circulating miRNA expression profiles of ESCC can help identify EC specific circulating miRNAs signatures for a new brand of screening, diagnostic and prognostic biomarkers. Studies can also be performed to clarify the functional role(s) of miRNAs in EC.
Potential in screening, surveillance and treatment of EC
So far, endoscopic biopsy and histopathological examinations are the golden standard for high-risk subject screening and early detection for EC worldwide. We can only identify 1%-2% early carcinomas and 15%-20% precancerous lesions in asymptomatic population aged higher than 35 years in high-incidence areas of EC through endoscopic biopsy and histopathological examinations. Yet nearly 80% asymptomatic populations were in the normal range. In other words, there exists over endoscopic application. Besides, as there are no sufficient experienced physicians in the countryside, the misdiagnosis and missed diagnosis would be inevitable. In addition, standard sterilizing procedure also restricts the wide application of endoscopy in asymptomatic population. Furthermore, the projected cost of mass screening in China for detection of cancers is increasing annually. An urgent and important problem to be solved is to diminish blindness in the screening, minify the range of endoscopy and elevate the detection sensitivity of early carcinoma in high risk subjects. Easily accessible and minimal invasive biomarkers for EC and for other diseases are much desirable. The PCR technique for detection and quantification of miRNA in the blood would be one of the promising methods of screening individuals for EC and other cancers because of its universal application, convenient management, low cost and high sensitivity. Rouet et al set up a model of qRT-PCR for serum RNA analysis, suggesting that its cost was only less than £1 for each clinical specimen when used in a group of 84 patients. Once the accuracy of detection is established, MiRNAs test should be introduced into the national EC and other disease screening programs. The best option might be that annual miRNA blood test in asymptomatic populations in high risk areas of EC, and then the patients with positive test result can choose endoscopic biopsy and histopathological examinations for final diagnosis.
Given the emerging evidence of miRNAs acting as oncogenic or tumor suppressor activities, it is important to seek approaches to interfere with the miRNA, and eventually, develop these as novel biomarkers into EC therapies. Scientists are making efforts to explore miRNA and utilize that in cancer. Meng et al showed that miRNA expression profiles changed during treatment with gemcitabine, and the sensitivity of cholangiocarcinoma tumor cells to this chemotherapy in vitro are increasing with the modulation of some miRNAs. On the contrary, it could be feasible to introduce tumor suppressor miRNA which are tissue-specific to the target gene, and then it may help prevent further progression, or even shrink EC. Yet, recently identified genomic and proteomic biomarkers, tumor cell mutations and microsatellite instability cannot be recommended for clinical use because of insufficient available data. Though recent studies on miRNA in EC are limited, the potential value of miRNAs as prognostic and predictive biomarkers in EC is elegantly highlighted and will be elucidated eventually. However, experimental miRNA therapy need to be validated comprehensively through studies involving different cohorts of patients before introduced into clinical practice.
Although much of the work on miRNA is still in its infancy, the previous studies have demonstrated the significant role(s) of miRNA in the initiation and progression of cancer and other diseases. Further exploration is required for better understanding their role in carcinogenesis of EC and for better application in the future. Notwithstanding there are still many questions to be answered about circulating miRNA, there is no doubt that further studies will lead to great progress in the future therapy of EC. The exploration of miRNA will improve our knowledge of the roles of these novel biomarkers, and further demonstrate their true potential in therapeutic methods.
Peer reviewer: Mitsuyoshi Urashima, MD, PhD, MPH, Division of Molecular Epidemiology, Jikei University School of Medicine, 3-25-8 Nishi-shimbashi, Minato-ku, Tokyo 105-8461, Japan
Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC. Frequent mutation of the p53 gene in human esophageal cancer.Proc Natl Acad Sci USA. 1990;87:9958-9961.
Wang LD, Zhou Q, Feng CW, Liu B, Qi YJ, Zhang YR, Gao SS, Fan ZM, Zhou Y, Yang CS. Intervention and follow-up on human esophageal precancerous lesions in Henan, northern China, a high-incidence area for esophageal cancer.Gan To Kagaku Ryoho. 2002;29 Suppl 1:159-172.
Headrick JR, Nichols FC 3rd, Miller DL, Allen MS, Trastek VF, Deschamps C, Schleck CD, Thompson AM, Pairolero PC. High-grade esophageal dysplasia: long-term survival and quality of life after esophagectomy.Ann Thorac Surg. 2002;73:1697-1702; discussion 1702-1703.
Reed CE. Surgical management of esophageal carcinoma.Oncologist. 1999;4:95-105.
Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma.Cancer Res. 2008;68:26-33.
Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers.Mol Cancer. 2007;6:60.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell. 1993;75:843-854.
Griffiths-Jones S. miRBase: the microRNA sequence database.Methods Mol Biol. 2006;342:129-138.
Kim VN, Nam JW. Genomics of microRNA.Trends Genet. 2006;22:165-173.
Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression?Biochem Soc Trans. 2008;36:1224-1231.
Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer. 2006;6:857-866.
Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes.Cell. 2005;120:21-24.
Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.Proc Natl Acad Sci USA. 2004;101:9740-9744.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA. MicroRNA expression profiles classify human cancers.Nature. 2005;435:834-838.
Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, Muckenthaler MU. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA).RNA. 2006;12:913-920.
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR. Real-time quantification of microRNAs by stem-loop RT-PCR.Nucleic Acids Res. 2005;33:e179.
Ørom UA, Kauppinen S, Lund AH. LNA-modified oligonucleotides mediate specific inhibition of microRNA function.Gene. 2006;372:137-141.
Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M, Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors.Nat Methods. 2009;6:63-66.
Franco-Zorrilla JM, Valli A, Todesco M, Mateos I, Puga MI, Rubio-Somoza I, Leyva A, Weigel D, García JA, Paz-Ares J. Target mimicry provides a new mechanism for regulation of microRNA activity.Nat Genet. 2007;39:1033-1037.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.Proc Natl Acad Sci USA. 2004;101:2999-3004.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M. A microRNA expression signature of human solid tumors defines cancer gene targets.Proc Natl Acad Sci USA. 2006;103:2257-2261.
Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.Nat Rev Cancer. 2006;6:259-269.
Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE, Litle VR. MicroRNA expression profiles of esophageal cancer.J Thorac Cardiovasc Surg. 2008;135:255-260; discussion 260.
Lee KH, Goan YG, Hsiao M, Lee CH, Jian SH, Lin JT, Chen YL, Lu PJ. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer.Exp Cell Res. 2009;315:2529-2538.
Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Harata K, Tanaka T, Fujii Y. Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR.Med Mol Morphol. 2009;42:102-109.
Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, Ajani JA, Wu X. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma.Clin Cancer Res. 2009;15:5744-5752.
Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival.Clin Cancer Res. 2009;15:6192-6200.
Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines.J Biol Chem. 2010;285:7986-7994.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth.Oncogene. 2007;26:2799-2803.
Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.Gastroenterology. 2006;130:2113-2129.
Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers.Oncogene. 2008;27:6667-6678.
Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.Cell Res. 2008;18:350-359.
Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway.J Clin Oncol. 2004;22:2954-2963.
Boyd J, Risinger JI, Wiseman RW, Merrick BA, Selkirk JK, Barrett JC. Regulation of microfilament organization and anchorage-independent growth by tropomyosin 1.Proc Natl Acad Sci USA. 1995;92:11534-11538.
Fraga MF, Esteller M. Towards the human cancer epigenome: a first draft of histone modifications.Cell Cycle. 2005;4:1377-1381.
Jérôme T, Laurie P, Louis B, Pierre C. Enjoy the Silence: The Story of let-7 MicroRNA and Cancer.Curr Genomics. 2007;8:229-233.
Li J, Feng CW, Zhao ZG, Zhou Q, Wang LD. A preliminary study on ras protein expression in human esophageal cancer and precancerous lesions.World J Gastroenterol. 2000;6:278-280.
Lord RV, O’Grady R, Sheehan C, Field AF, Ward RL. K-ras codon 12 mutations in Barrett’s oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction.J Gastroenterol Hepatol. 2000;15:730-736.
Bos JL. ras oncogenes in human cancer: a review.Cancer Res. 1989;49:4682-4689.
Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients.Clin Cancer Res. 2006;12:7322-7328.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A. Circulating microRNAs as stable blood-based markers for cancer detection.Proc Natl Acad Sci USA. 2008;105:10513-10518.
Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.Cell Res. 2008;18:997-1006.
Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N. Serum microRNAs are promising novel biomarkers.PLoS One. 2008;3:e3148.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.Br J Haematol. 2008;141:672-675.
Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.Gynecol Oncol. 2009;112:55-59.
Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.Gynecol Oncol. 2008;110:13-21.
Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer.Clin Lung Cancer. 2009;10:42-46.
Rosell R, Wei J, Taron M. Circulating MicroRNA Signatures of Tumor-Derived Exosomes for Early Diagnosis of Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2009;10:8-9.
Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects.BMC Res Notes. 2009;2:89.
Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer.Int J Cancer. 2010;127:118-126.
Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening.Gut. 2009;58:1375-1381.
Rouet F, Rouzioux C. HIV-1 viral load testing cost in developing countries: what’s new?Expert Rev Mol Diagn. 2007;7:703-707.
Blenkiron C, Miska EA. miRNAs in cancer: approaches, aetiology, diagnostics and therapy.Hum Mol Genet. 2007;16 Spec No 1:R106-R113.
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.J Clin Oncol. 2006;24:5313-5327.